Fas Ligand/TNFSF6 Antibody [Alexa Fluor™ Plus 647]

• Reactivity: Mu
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 647

Fas Ligand/TNFSF6 Antibody [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects mouse Fas Ligand/TNFSF6 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross‑reactivity with recombinant human Fas Ligand is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Fas Ligand/TNFSF6 Antibody [Alexa Fluor™ Plus 647]

• apoptosis (APO-1) antigen ligand 1
• Apoptosis antigen ligand
• APT1LG1CD95L
• APTL
• CD178 antigen
• CD178
• CD95L
• CD95-L
• Fas antigen ligand
• Fas ligand (TNF superfamily, member 6)
• Fas Ligand
• FASLCD95 ligand
• FASLG
• TNFSF6
• TNFSF6FasL
• tumor necrosis factor (ligand) superfamily, member 6
• tumor necrosis factor ligand superfamily member 6

Background

Fas ligand (FasL) is a 40 kDa type II membrane protein belonging to the TNF family. In the new TNF super family nomenclature, FasL is referred to as TNFSF6. The specific receptor for FasL is Fas (CD95, Apo-1), a 45 kDa type I transmembrane protein that is a member of the TNF receptor family. FasL is predominantly expressed on activated T cells and NK cells, while Fas is expressed on various types of cells. The Fas/FasL system plays a crucial role in modulating immune response by inducing cell apoptosis to maintain homeostasis, self-tolerance of lymphocytes, and immune privilege. FasL was reported to be a potent chemoattractant for neutrophils, suggesting a novel proinflammatory function of this molecule. Like other members of the TNF family, the membrane-bound FasL can be cleaved by metalloproteinase to generate the soluble Fas ligand (sFasL) which is mainly a non-covalently linked homotrimer. It has been shown that the membrane-bound TNF‑ alpha and FasL are primary activators of their receptors. In contrast to soluble TNF‑ alpha which has potent cytotoxicity, sFasL is much less cytotoxic. Studies have shown that sFasL may competitively inhibit the killing effect of membrane FasL indicating that the cleaving of membrane FasL might be a mechanism to down‑regulate their activities.

1. Suda, T. et al. (1993) Cell 75:1169.
2. Kägi, D. et al. (1994) Science 265:528.
3. Schneider, P. et al. (1998) J. Exp. Med. 187:1205.
4. Seino, K. et al. (1998) J. Immunol. 161:4484.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.